Robert; Bruno

Patent Applications and Registrations

Patent applications and USPTO patent grants for Robert; Bruno.The latest application filed is for "polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor".

Company Profile

4.11.15

Robert; Bruno - Montpellier FR
ROBERT; Bruno - Montpelllier FR
Robert; Bruno - Paris FR
ROBERT; Bruno - Valflaunes FR
ROBERT; Bruno - Montpellier Cedex 5 FR
Robert; Bruno - Saint Hippolyte du Four FR
Robert; Bruno - Epalinges CH
Robert; Bruno - Saint Hippolyte de Four FR
Robert, Bruno - Saint Hippocyte Du Fort FR
Robert; Bruno - Grand-Duchy LU

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Monoclonal antibodies binding to the CD160 transmembrane isoform Grant 11,186,635 - Bensussan , et al. November 30, 2	2021-11-30
Polypeptides For Preparing Drug Conjugates Capable Of Promoting Apoptosis In A Cell Expressing An Orexin Receptor App 20210188983 - ROBERT; Bruno ; et al.	2021-06-24
Human monoclonal antibodies against orexin receptor type 1 Grant 10,758,615 - Couvineau , et al. Sep	2020-09-01
Imaging method, and system, for obtaining a super-resolution image of an object Grant 10,527,837 - Robert , et al. J	2020-01-07
Human monoclonal antibodies against AXL Grant 10,398,774 - Robert , et al. Sep	2019-09-03
Monoclonal Antibodies Binding To The Cd160 Transmembrane Isoform App 20190256595 - BENSUSSAN; Armand ; et al.	2019-08-22
Receptor-binding Domains Ligands For The Detection, Diagnosis And Treatment Of Pancreatic Cancer App 20180280549 - TOUHAMI; Jawida ; et al.	2018-10-04
Human Monoclonal Antibodies Against Orexin Receptor Type 1 App 20180030135 - COUVINEAU; Alain ; et al.	2018-02-01
Human Monoclonal Antibodies Against Orexin Receptor Type 1 App 20180002421 - COUVINEAU; Alain ; et al.	2018-01-04
Imaging Method, And System, For Obtaining A Super-resolution Image Of An Object App 20170351080 - ROBERT; Bruno ; et al.	2017-12-07
Human Monoclonal Antibodies Against Axl App 20170340734 - ROBERT; Bruno ; et al.	2017-11-30
Targeted CD1d molecules Grant 9,809,654 - Robert , et al. November 7, 2	2017-11-07
Anti-Axl antibodies and uses thereof Grant 9,409,988 - Robert , et al. August 9, 2	2016-08-09
Anti-Axl antibodies and uses thereof Grant 9,249,228 - Robert , et al. February 2, 2	2016-02-02
Anti-axl Antibodies And Uses Thereof App 20140302041 - Robert; Bruno ; et al.	2014-10-09
Anti-axl Antibodies And Uses Thereof App 20140227283 - Robert; Bruno ; et al.	2014-08-14
Multicomponent conjugates which bind to target molecules and stimulate T cell lysis App 20070237771 - Donda; Alena ; et al.	2007-10-11
Targeted cd1d molecules App 20060269540 - Robert; Bruno ; et al.	2006-11-30
Multicomponent conjugates which bind to target molecules and stimulate T cell lysis App 20040143094 - Donda, Alena ; et al.	2004-07-22
Multicomponent conjugates which bind to target molecules and stimulate cell lysis App 20040068100 - Mach, Jean-Pierre ; et al.	2004-04-08
Mobile tracking and positioning system Grant 6,169,497 - Robert January 2, 2	2001-01-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.